Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.105 SGD | -4.55% | 0.00% | 0.00% |
Income Statement Evolution (Annual data)
Fiscal Period: June | 2021 | 2022 | 2023 |
---|---|---|---|
Net sales 1 | 12.92 | 13.81 | 16.23 |
EBITDA 1 | -6.623 | -11.01 | -10.91 |
EBIT 1 | -8.662 | -13.32 | -13.74 |
Operating Margin | -67.06% | -96.43% | -84.63% |
Earnings before Tax (EBT) 1 | -9.386 | -14.48 | -18.96 |
Net income 1 | -9.349 | -12.43 | -18.07 |
Net margin | -72.38% | -89.98% | -111.32% |
EPS 2 | -0.0175 | -0.0193 | -0.0257 |
Free Cash Flow | - | 3.475 | -19.28 |
FCF margin | - | 25.17% | -118.78% |
FCF Conversion (EBITDA) | - | - | - |
FCF Conversion (Net income) | - | - | - |
Dividend per Share | - | - | - |
Announcement Date | 2/2/24 | 2/2/24 | 2/2/24 |
Balance Sheet Analysis
Fiscal Period: June | 2021 | 2022 | 2023 |
---|---|---|---|
Net Debt 1 | 81.7 | 71.2 | 69.5 |
Net Cash position 1 | - | - | - |
Leverage (Debt/EBITDA) | -12.34 x | -6.466 x | -6.371 x |
Free Cash Flow | - | 3.48 | -19.3 |
ROE (net income / shareholders' equity) | - | -25.6% | -38.3% |
ROA (Net income/ Total Assets) | - | -4.8% | -5.14% |
Assets 1 | - | 258.6 | 351.4 |
Book Value Per Share 2 | 0.1100 | 0.0800 | 0.1300 |
Cash Flow per Share 2 | 0.0200 | 0.0200 | 0.0300 |
Capex 1 | 5.45 | 4.09 | 14.4 |
Capex / Sales | 42.16% | 29.61% | 88.93% |
Announcement Date | 2/2/24 | 2/2/24 | 2/2/24 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
- Stock Market
- Equities
- 9G2 Stock
- Financials Singapore Institute of Advanced Medicine Holdings Ltd.